Keystone Medical Group | |
2417 Welsh Rd, Suite 201, Philadelphia, PA 19114-2213 | |
(215) 914-5122 | |
Not Available |
Full Name | Keystone Medical Group |
---|---|
Type | Facility |
Speciality | Internal Medicine |
Location | 2417 Welsh Rd, Philadelphia, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003244419 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
111N00000X | Chiropractor | (* (Not Available)) | Secondary |
207R00000X | Internal Medicine | (* (Not Available)) | Primary |
225100000X | Physical Therapist | (* (Not Available)) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Keystone Medical Group 1220 Bridle Estates Dr, Yardley, PA 19067-3957 Ph: () - | Keystone Medical Group 2417 Welsh Rd, Suite 201, Philadelphia, PA 19114-2213 Ph: (215) 914-5122 |
News Archive
James Oliver picked up an Xbox game controller, looked up to a video screen and used the device's buttons and joystick to fly through a patient's chest cavity for an up-close look at the bottom of the heart.
Researchers have determined that new mothers exposed to cigarette smoke in their homes, stop breastfeeding sooner than women not exposed to second-hand smoke.
For 40 percent of the estimated six million American couples battling infertility, the problem lies with the man. But help may be on the way.
During a town hall meeting Tuesday on health care reform, Senator Arlen Specter (D-Pa.) stated his opposition to legislation that would cover illegal aliens. Specter has been a long-time champion of amnesty for illegal aliens, he was the author of the 2006 amnesty bill (S. 2611) that was widely rejected by the American people.
The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.
› Verified 3 days ago